C

Celldex Therapeutics

Develops antibody-based therapies targeting inflammatory diseases

Associate Director CMC Drug Substance

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-timeHampton, NJ, USA

About the Job

Requirements

  • A Master’s degree in Chemical Engineering, Biochemical Engineering, Biochemistry, Biological Sciences, or a science-related field.
  • At least 8 years of progressive experience in biotechnology, pharmaceutical, or biologics manufacturing environments.
  • At least 3 years of experience managing or working with biologics CDMOs.
  • At least 2 years of experience working with late-phase biologics programs.
  • At least 2 years of experience authoring CMC technical writing.
  • Proficiency in MS Outlook, Word, Excel, Project, PowerPoint, and Visio.
  • Ability to travel 10–15% of the time.

Responsibilities

  • Support process characterization and validation for commercialization of pipeline drug candidates.
  • Support GMP external manufacturing of clinical or commercial biologics drug substance.
  • Review CDMO batch records, protocols, and reports; lead or support troubleshooting, process risk analysis, and manufacturing investigations.
  • Serve as a person-in-plant to assist in managing CDMO activities.
  • Lead technology transfer of pipeline drug candidates to external CDMOs.
  • Support authoring Module 3 of the drug substance Common Technical Document for regulatory submissions.
  • Support the Continuous Process Verification program for commercial biologics manufacturing.
  • Collaborate with internal and external cross-functional teams, including analytical, formulation, quality assurance, and regulatory teams, to support batch release, manufacturing investigations, testing, and stability programs.

About the Company

Celldex Therapeutics

Develops antibody-based therapies targeting inflammatory diseases

Celldex Therapeutics develops antibody-based therapies for inflammatory, allergic, and autoimmune diseases, focusing on mast cell biology. Its lead program barzolvolimab is a humanized monoclonal antibody that inhibits KIT, reducing mast cell activity and inflammation; its pipeline includes other antibodies designed to engage the immune system or modulate disease pathways. The company leverages partnerships and licensing in addition to developing its own therapies to create a breadth of programs in its target areas. Its goal is to deliver therapies that lessen inflammation and autoimmune activity by targeting mast cells and related signaling pathways.

Company size
201-500
Company stage
IPO
Headquarters
Hampton, NJ
Founded
1983

Recently Posted Jobs

Explore more opportunities at Celldex Therapeutics

See more jobs